A clinical trial of estrogen-replacement therapy after ischemic stroke.

By C. Viscoli, L. Brass, W. Kernan, P. Sarrel, S. Suissa, R. Horwitz. New England Journal of Medicine, 2001

830 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Genetics

View Paper: https://www.semanticscholar.org/paper/3ff2899dc5073f484685a8d564ee001ad35ef19c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Gustavo Saposnik
2. M. Bousser
3. L. McCullough
4. I. Awad
5. M. Chireau
6. Wende N. Fedder
7. I. Piña
8. P. Ringleb

Citations in the corpus

• The 2012 Hormone Therapy Position Statement of The North American Menopause Society (2012, neutral): “Stroke risk was not significantly increased in the Heart and Estrogen/Progestin Replacement Study(52) and the Women’s Estrogen for Stroke Trial secondary prevention trials.(53) The Women’s International Study of long Duration Oestrogen after Menopause RCT found no excess risk of stroke in EPT users ”
• Guidelines for the Prevention of Stroke in Women: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association (2014, background): “Two large clinical trials examined women with established vascular disease: the Heart and Estrogen/Progestin Replacement Study (HERS) and Women’s Estrogen for Stroke Trial (WEST).(250,251) Stroke events (including any stroke and IS) were similar for women allocated to an estrogen or to placebo.”